AstraZeneca PLC (ADR) (AZN) In Respiratory Drug Deal With Circassia Pharmaceuticals

In an effort to enhance collaboration with Circassia Pharmaceuticals, AstraZeneca PLC (ADR) (NYSE:AZN) has acquired an equity stake valued.....»»

Category: topSource: insidermonkeyMar 20th, 2017

Boston-based Pieris adds AstraZeneca as R&D partner in $45M deal

Shares of Pieris Pharmaceuticals soared on Wednesday after the tiny Boston biotech announced yet another collaboration with a big pharma company, this time grabbing $45 million upfront from AstraZeneca to develop inhalable respiratory disease drugs.....»»

Category: topSource: bizjournalsMay 3rd, 2017

Indian firm a front-runner to acquire Mallinckrodt"s generic drug business: Report

India-based Intas Pharmaceuticals reportedly has emerged as a front-runner to acquire Mallinckrodt's generic drug business in a deal that could be worth $1.5 billion. Intas, the largest privately held pharmaceutical company in India, is one of two bi.....»»

Category: topSource: bizjournalsNov 2nd, 2017

Novartis to Pay $3.9 Billion for Radio-Pharmaceuticals Firm

Novartis said it has agreed to acquire Advanced Accelerator Applications for $3.9 billion, a deal that would boost its oncology portfolio as generic competition eats into sales of blockbuster blood-cancer drug Gleevec......»»

Category: smallbizSource: wsjOct 30th, 2017

Wall Street"s most hated pharma company just lost a lifeline

Markets InsiderA court ruling on Tuesday left Mallinckrodt Pharmaceuticals without protection from 11 patents on its drug Inomax, a hypoxic respiratory failure drug that made up 15% of the company's r.....»»

Category: topSource: businessinsiderSep 5th, 2017

AstraZeneca and Takeda Ink Deal to Develop Parkinson"s Drug

AstraZeneca (AZN) and Takeda Pharmaceutical Company entered into an agreement to jointly develop and .....»»

Category: personnelSource: nytAug 30th, 2017

Mystery at AstraZeneca: Is CEO Pascal Soriot Staying or Going?

Shares in the U.K. drug giant fell sharply after a news outlet reported he was moving to lead Teva Pharmaceuticals, an Israeli generics drugmaker that has been looking for a new chief for months......»»

Category: smallbizSource: wsjJul 13th, 2017

GSK"s new pharma head to join in September after AstraZeneca tussle

LONDON (Reuters) - GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca......»»

Category: topSource: reutersJun 19th, 2017

Valeant Pharmaceuticals: Bigger is Better

Though the sale of its iNova unit brings Valeant Pharmaceuticals close to meeting its goal of $5 billion in debt reduction by February 2018, the drug maker may need to step up its deal making if it wants to take a real bite out of its debt load......»»

Category: blogSource: barronsJun 8th, 2017

AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan

AstraZeneca PLC AZN has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grünenthal, a German pharmaceutical company. read more.....»»

Category: blogSource: benzingaJun 8th, 2017

AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan

AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company. AstraZeneca PLC AZN has in.....»»

Category: topSource: zacksJun 8th, 2017

Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka

Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S. Teva .....»»

Category: topSource: zacksMay 16th, 2017

Pieris Pharma stock soars 54% on news of $57.5 mln AstraZeneca deal

Pieris Pharmaceuticals Inc. shares surged as much as 54% in premarket trade Wednesday on news of the company's $57.5 million deal with AstraZen.....»»

Category: topSource: marketwatchMay 3rd, 2017

Nuventra founder inks deal for new venture that could be worth as much as $49 million

A Research Triangle Park-based virtual drug development company 1st Order Pharmaceuticals (1OP) has inked a deal with Canada’s Xenon Pharmaceuticals (Nasdaq: XENE) that could be worth as much as $49 million. 1OP was founded in 2013 by Christoph.....»»

Category: topSource: bizjournalsApr 28th, 2017

Concert rebuffed $250M buyout offer from Vertex before CF drug deal

Lexington-based Concert Pharmaceuticals rebuffed a $250 million buyout offer from Vertex Pharmaceuticals in November before ultimately striking a deal earlier this month to sell a cystic fibrosis drug to the Boston company for $160 million, according t.....»»

Category: topSource: bizjournalsMar 24th, 2017

AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal

London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application .....»»

Category: topSource: zacksMar 20th, 2017

Marathon Sells Muscular-Dystrophy Drug to PTC After Pricing Scrutiny

Marathon Pharmaceuticals has struck a deal to sell its muscular dystrophy treatment to PTC Therapeutics, two weeks after a group of U.S. senators began scrutinizing the steroidal drug’s pricing......»»

Category: smallbizSource: wsjMar 16th, 2017

$160M deal with Concert helps Vertex maintain dominance in cystic fibrosis

Vertex Pharmaceuticals' move on Monday to acquire a once-a-day cystic fibrosis drug for $160 million from a 69-employee Lexington-based biotech could help the Boston company maintain its "dominant" position in the CF pharmaceuticals market, accordi.....»»

Category: topSource: bizjournalsMar 6th, 2017

Pieris Pharmaceuticals" stock soars after exclusive license deal with Japan"s ASKA

Shares of Pieris Pharmaceuticals Inc. soared 16% in premarket trade Monday, after the drug maker announced an exclusive license deal with Japan's ASKA Pharmaceutical Co. Ltd. for the development and comm.....»»

Category: topSource: marketwatchFeb 27th, 2017

MedImmune gets OK from China to pursue arthritis drug in joint venture deal

Gaithersburg-based MedImmune is expanding its footprint in China's drug market after receiving a permit to begin clinical trials there on a biologic therapy for rheumatoid arthritis. MedImmune, which is the R&D arm for London-based AstraZeneca (NYSE:.....»»

Category: topSource: bizjournalsJan 19th, 2017

Japan"s Takeda ready for fresh acquisitions after $5.2 billion Ariad deal

Japan's Takeda Pharmaceutical Co said it has the financial capacity for fresh acquisitions to bolster its drug portfolio after agreeing on Monday to acquire cancer drug maker Ariad Pharmaceuticals in a $5.20 billion deal......»»

Category: topSource: foxnewsJan 10th, 2017